Skip to content

Psychedelics: Threshold of a Therapeutic Revolution

David J Heal, Sharon L. Smith, Sean J Belouin, Jack E Henningfield

Neuropharmacology May 27, 2023 DOI: 10.1016/j.neuropharm.2023.109610 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Anxiety Psilocybin
Keywords Hallucinogen Psychotherapist
Citations 50
Key findings The FDA has granted breakthrough therapy designations for psilocybin in treatment-resistant depression and major depressive disorder, and for MDMA in PTSD, with ongoing clinical trials for multiple indications.

Abstract

This Special Issue of Neuropharmacology on psychedelics provides a timely and comprehensive update on progress following the previous Neuropharmacology Special Issue "Psychedelics: New Doors, Altered Perceptions". Remarkable advances have been made in basic and clinical research on psychedelics in the five years since 2018. It is partly based on the seminar series focused on psilocybin organized by the National Institutes of Health (NIH), USA from April to June 2021, the "NIH Psilocybin Research Speaker Series". Participants were world leading experts, including scientists, medical practitioners, clinical psychologists and oncologists, and attendees from additional disciplines of patient advocacy, law, government science policy and regulatory policy. To provide a global perspective, their contributions are complemented with reviews by some of the world's most eminent scientists in the field. The US Food and Drug Administration (FDA) has granted two breakthrough therapy designations for psilocybin in treatment resistant depression (TRD) in 2018 and major depressive disorder (MDD) in 2019, as well as for MDMA for the treatment of post-traumatic stress disorder (PTSD) in 2017. Clinical trials are in progress to assess the therapeutic value of psilocybin in MDD and TRD, and in other indications such as cancer-related anxiety and depression, anorexia, PTSD, substance use disorders and various types of chronic pain. The contributors' insights should assist basic and applied science for transition of psychedelics from bench to potential mainstream therapies. The implications are global, because FDA approval of these new medicines will increase international interest and efforts.

Comparable studies

Other narrative reviews on psilocybin for anxiety, most cited first.

Study Year Design Participants
Psychedelics as anti-inflammatory agents Animal models and cellular studies 2018 Review
Ayahuasca: Pharmacology, neuroscience and therapeutic potential 2016 Review
Psychedelic Drugs in Biomedicine 2017 Review
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses 2020 Review
Psychedelics and health behaviour change 2021 Review

Citations in the library

Cited by 39

and 34 more in the library

Cites 18

and 13 more in the library

Related reading

Explore topics

Anxiety Psilocybin Addiction Depression MDMA PTSD Psychedelic-assisted therapy

By condition and practice

Psilocybin for anxiety